INTRODUCTION
The process of diagnosis of small blue round cell tumors (SBRCT) is a difficult task from both an oncological and pathological perspective. This group of neoplasms contains a considerable number of different tumors, which have similar histological features under light microscopy. Therefore, a great help in making this diagnosis and choosing the correct treatment has been the introduction of techniques such as immunohistochemistry and polymerase chain reaction (PCR) (1) (2) (3) . Despite the great advances in technology, problems still exist with regards to differentiating between similar tumors from that group. This difficulty is evident in the differentiation of the Ewing sarcoma family of tumors (ESFT) from lymphoblastic lymphoma (LBL) (4, 5) .
Here, we report a patient with common type acute lymphoblastic leukemia (ALL), bulk extramedullary disease, a chromosome 22 (EWSR1) rearrangement and a positive EWS/FLI1 fusion transcript initially presented as a subcutaneous lymphoma masquerading as Ewing sarcoma (EWS).
CASE REPORT
The patient was a 2-year-old female, who was referred to our surgical department due to a subcutaneous mass in the left parietal region. The mass was not painful and her parents did not report any other abnormalities. There was no previous significant illnesses in her past medical history. The physical examination revealed that she was slightly underweight. There was no organomegaly, enlarged lymph nodes, or other abnormalities. The complete blood count (CBC) was normal at that time. There was no evidence of leukemic blasts or tumor cells in the peripheral blood smear.
Within a few days of presentation, the patient underwent a scheduled surgical excision of the parietal mass. The initial pathological findings of the resected tissue showed that the tumor consisted of clusters of atypical small cells with hyperchromatic nuclei ( Figure   1a ). Immunohistochemistry of the tumor tissue demonstrated a positive reaction to the antigens for CD99 (Figure 1b) , neuron specific enolase and synaptophysin, but the studies were negative for leukocyte common antigen (LCA). Reverse-transcriptase polymerase chain reaction (RT-PCR) analysis of the fresh pathological specimen was performed as previously described (6) . It showed the existence of an EWS/FLI1 type 2 transcript, which is commonly associated with ESFT ( Figure 1c) (3) . A EWSR1 rearrangement from formalin-fixed paraffinembedded tumor tissue was subsequently confirmed by fluorescence in situ hybridization (FISH) (7).
The patient was diagnosed with an extraosseous EWS, and she was transferred to our oncology department. Upon admission, another CBC with a differential was performed. This showed white blood cells of 12.5×10 9 /L, a hemoglobin level of 10.3 g/dl and normal platelet values of 168×10 9 /L. Serum levels of lactate dehydrogenase and uric acid were found to be within the normal ranges. Malignant blasts (17%) were found in the peripheral blood smear.
That finding, together with EWS staging requirements, necessitated a bone marrow examination. The bone marrow specimen was obtained from the sternum and morphologically showed no elements of EWS, but was infiltrated with 65% lymphoblasts (Figure 2a ). These were positive for periodic acid-Schiff (PAS) and negative for peroxidase, acid phosphatase, and alpha-naphthylacetate esterase (ANAE). Flow cytometric immunophenotyping of the bone marrow material was positive for terminal deoxynucleotidyl transferase (TdT), CD10, CD19, CD34, cytoplasmic expression of CD79a (cCD79a) and HLA-DR, all of which was consistent with the diagnosis of common B cell precursor type ALL. Immunocytochemistry of the bone marrow specimen also confirmed CD10 positivity (Figure 2b ). Furthermore, RT-PCR analysis of the bone marrow was performed as previously described (8) . The results were negative for TEL/AML-1, BCR/ABL, ALL-1/AF-4 transcripts. Polymerase chain reaction (PCR) analysis of the bone marrow for immunoglobulin heavy chain gene rearrangement (IgH-R) was carried out as described previously and was found to be positive (9) . However, the bone marrow EWS/FLI1 transcript analysis was not performed by RT-PCR at that time due to the scarcity of the specimen; the positive result for the bone marrow EWSR1 rearrangement was confirmed by FISH (Figure 2c ) (7).
The original diagnosis was challenged by these results, and further investigations of the excised tumor were deemed to be necessary. More detailed immunohistochemistry of the subcutaneous mass showed positivity for CD10, CD34, CD79a, CD99, TdT and PAX5. CD20
antigen, a common marker in B cell lymphomas was negative. We also found a high positivity for the Fli1 protein, which is uncommon in lymphomas, although it has been reported (2).
PCR analysis for IgH-R within the subcutaneous tumor was also positive and showed an identical rearrangement to the type that had been found in the analysis of the bone marrow The same genetic rearrangement can be present across malignancies of different phenotypes. The presence of BCR/ABL in chronic myeloid leukemia (CML) and ALL is the most classic example. EWSR1 and ETS (FLI1, ERG) rearrangements associated with ESFT have also been described in hematopoietic malignancies (14, 15) . One case of acute myeloid leukemia (AML) with t(11;22)(q24;q12) and a case of granulocytic sarcoma masquerading as EWS have been reported (16, 17) . Also, one case of concomitant EWS and ALL (18), as well as the case of EWS as second malignant neoplasm after ALL, have been described (19) . (11)) and red (der(22)) demonstrates a rearrangement of the EWS gene.
